Abstract Background and Objective Biologics for psoriasis, especially anti-tumor necrosis
factor-α therapies, may reactivate hepatitis B virus (HBV) or hepatitis C virus (HCV) …

Safety data for secukinumab in patients with psoriasis and viral hepatitis are lacking. The
aim of this study is to investigate the risk of reactivation of hepatitis B virus (HBV)/hepatitis C …

Background The burden of hepatitis B virus (HBV) infection in China is high. The safety and
efficacy of secukinumab in psoriasis patients with HBV infection have not been fully …

Background: There is limited long-term, real-world evidence on the efficacy and safety in
patients with plaque psoriasis treated with secukinumab. We present results at 136 weeks in …

Purpose: Biologic therapy in psoriatic patients with multiple comorbidities is challenging due
to worsening of associated diseases and possible side effects of concomitant medications …

The case reported describes a 48-year-old man with congenital hepatitis B receiving
secukinumab for treatment of psoriasis. Some biologic therapies have been associated with …

Background Some biologics for psoriasis, especially anti-tumor necrosis factor (TNF)-α
therapies, may re-activate latent tuberculosis (TBC) infection with consequent morbidity and …

Biological therapies used in psoriasis treatment pose a risk of reactivation of hepatitis B virus
(HBV) infection. This risk occurs not only in patients with HB surface antigen (HBsAg)(+) but …

Abstract Introduction Plaque psoriasis (PsO), characterized by demarcated, erythematous,
scaly skin, can have a substantial negative impact on patients' quality of life. This …

Importance Approximately one-quarter of the global population have latent tuberculosis
infection (LTBI), and tuberculosis (TB) is accountable for more than 1.5 million deaths …